Legal & RegulatoryEvent: September 8, 2026
PILA PHARMA received regulatory approval for its next 3-month study in people with obesity using an oral small-molecule TRPV1 antagonist.
Published
Signal category
Legal & Regulatory
Quote
“our next 3-month study in people with #obesity with our oral small-molecule #TRPV1 antagonist!”
— PILA PHARMA team
Company
PILA PHARMA
We are a #TRPV1 focused company developing oral treatments for Type-2 #Diabetes & #Erythromelalgia
- Industry
- Biotechnology Research
- Location
- Malmö, SE
- Company size
- 5 employees
PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
Founded 2014